Ranbaxy Laboratories Limited (Ranbaxy) announced today that the company has obtained approval from the Drug Controller General of India (DCGI) to initiate phase-III human clinical trials in India for its new Anti-Malaria combination molecule, RBx 11160 (Arterolane maleate and piperaquine phosphate). The clinical trial will be conducted on patients from India, Africa and South and South-East Asian countries.
The details can be read here.
No comments:
Post a Comment